Jane Street
AXSM icon

Jane Street’s Axsome Therapeutics AXSM Stock Holding History

Jane Street’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$22.3M Sell
120,900
-49,800
-29% -$10.8M ﹤0.01% 1981
2026
Q2 		$41.8M Buy
170,700
+88,200
+107% +$19.1M ﹤0.01% 1565
2026
Q1 		$13.9M Buy
82,500
+27,700
+51% +$4.78M ﹤0.01% 2140
2025
Q4 		$10M Buy
54,800
+1,500
+3% +$209K ﹤0.01% 2314
2025
Q3 		$6.47M Buy
53,300
+32,500
+156% +$3.66M ﹤0.01% 3031
2025
Q2 		$2.17M Sell
20,800
-63,100
-75% -$6.68M ﹤0.01% 4289
2025
Q1 		$9.8M Sell
83,900
-76,500
-48% -$8.72M ﹤0.01% 2012
2024
Q4 		$13.6M Buy
160,400
+52,100
+48% +$4.79M ﹤0.01% 1614
2024
Q3 		$9.7M Buy
108,300
+77,000
+246% +$6.72M ﹤0.01% 1936
2024
Q2 		$2.52M Sell
31,300
-225,900
-88% -$16.7M ﹤0.01% 4106
2024
Q1 		$20.5M Buy
257,200
+198,100
+335% +$16.6M ﹤0.01% 1165
2023
Q4 		$4.7M Sell
59,100
-10,400
-15% -$695K ﹤0.01% 2943
2023
Q3 		$4.86M Sell
69,500
-21,000
-23% -$1.57M ﹤0.01% 2652
2023
Q2 		$6.5M Sell
90,500
-13,000
-13% -$959K ﹤0.01% 2396
2023
Q1 		$6.38M Sell
103,500
-56,400
-35% -$3.71M ﹤0.01% 2120
2022
Q4 		$12.3M Buy
159,900
+1,300
+0.8% +$77.7K 0.01% 1416
2022
Q3 		$7.08M Sell
158,600
-98,400
-38% -$4.92M ﹤0.01% 2112
2022
Q2 		$9.8M Buy
257,000
+226,800
+751% +$7.17M ﹤0.01% 1760
2022
Q1 		$1.25M Sell
30,200
-20,900
-41% -$648K ﹤0.01% 5661
2021
Q4 		$1.93M Sell
51,100
-73,800
-59% -$2.72M ﹤0.01% 4569
2021
Q3 		$4.12M Sell
124,900
-153,600
-55% -$5.99M ﹤0.01% 3061
2021
Q2 		$18.8M Sell
278,500
-85,000
-23% -$5.1M 0.01% 1120
2021
Q1 		$20.6M Buy
363,500
+170,800
+89% +$12M 0.01% 945
2020
Q4 		$15.7M Sell
192,700
-153,300
-44% -$11.5M 0.01% 1049
2020
Q3 		$24.7M Buy
346,000
+3,000
+0.9% +$234K 0.01% 662
2020
Q2 		$28.2M Buy
343,000
+303,100
+760% +$23.3M 0.02% 578
2020
Q1 		$2.35M Buy
39,900
+18,600
+87% +$1.52M ﹤0.01% 1864
2019
Q4 		$2.2M Buy
+21,300
New +$860K ﹤0.01% 1837

Other funds holding AXSM

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 42.55% 1-Year Est. Return
Alethea Capital Management
Alethea Capital Management Mercer Island, Washington $197M AUM 51.86% 1-Year Est. Return

Jane Street's AXSM Position: Q3 2026 in Review

Jane Street reduced its Axsome Therapeutics (AXSM) stake by 99% in Q3 2026, selling an estimated $87.1M and leaving 3,558 shares worth $656K. The position accounts for ﹤0.01% of the portfolio, ranked #7402.

Jane Street first reported a position in AXSM in Q1 2019 and has held it in 30 quarters since. The position peaked at $98.9M in Q2 2026. 348 funds tracked by Wall St. Rank hold AXSM as of Q3 2026.

  • Jane Street held 3,558 shares of Axsome Therapeutics worth $656K as of Q3 2026.
  • Jane Street sold 400,437 Axsome Therapeutics shares in Q3 2026, an estimated $87.1M.
  • Axsome Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q3 2026, its #7402 holding.
  • Jane Street first reported a position in Axsome Therapeutics in Q1 2019 and has held it in 30 quarters since.
  • Jane Street's Axsome Therapeutics position peaked at $98.9M in Q2 2026.
  • 348 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2026.

Based on Jane Street's 13F filing for Q3 2026, filed 12 Nov 2026.